Labcorp upgraded to Outperform from In Line at Evercore ISI

Evercore ISI upgraded Labcorp (LH) to Outperform from In Line with a price target of $265, up from $260. The firm sees upside to consensus EPS estimates for 2025 and later, largely driven by “still-solid” base testing growth, as well as Invitae and diagnostic margin expansion, the analyst tells investors. 2025 lab volume growth should remain solid, even if utilization trends soften somewhat, the analyst added.